Current report
Open the filing on sec.gov
BioVie Inc. (BIVI)
Nasdaq: BIVI · Pharmaceutical Preparations · Carson City, NV · filing with the SEC since 2013
The companyfiscal 2026, as filed
Revenuen/a
Net income-$22.1M-25.8%
Earnings per share$-3.05+74.8%
Operating cash flow-$19.0M+0.0%
Cash$9.0M-48.8%
Debtn/a
Shareholders’ equity$10.3M-46.0%
Shares, diluted7,245,928+390.5%
Return on equity-214.9%
The recordfrom its filings
Filings in 202641
Newest filingNov 10 · 8-K
Annual reportAug 13, 2026
Quarterly reportNov 6, 2026
Next report due10-Q by Feb 14
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents granted3
Filer categoryNon-accelerated filer<br>Smaller reporting company
Trailing twelve months to Sep 2026Cash from operations -$18.9Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in USD. Nothing here is a forecast.
News
Large holder update, amended
Open the filing on sec.gov
Quarterly report
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Shelf offering
Open the filing on sec.gov
Shelf offering
Open the filing on sec.gov
Shelf offering
Open the filing on sec.gov
Proxy statement
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Shelf offering
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.